Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Core Viewpoint - Kyverna Therapeutics, Inc. has initiated an underwritten public offering of $100 million in common stock, with an option for underwriters to purchase an additional $15 million [1] Group 1: Offering Details - The public offering consists of $100 million in shares, with a 30-day option for underwriters to buy up to an additional $15 million [1] - J.P. Morgan, Leerink Partners, Morgan Stanley, and Wells Fargo Securities are acting as joint book-running managers for the offering [1] - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1] Group 2: Company Overview - Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases [4] - The company's lead therapy candidate is miv-cel, an autologous CD19-targeting CAR T-cell therapy [4] - Kyverna is advancing its neuroimmunology franchise with completed and ongoing registrational trials for conditions such as stiff person syndrome and generalized myasthenia gravis [4]